Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

The purpose of the study is to evaluate pharmacokinetic equivalence, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of

purified protein derivative
phototherapy
systemic therapy
tuberculosis
ustekinumab
  • 5 views
  • 15 Sep, 2021
  • 74 locations
  • 0 views
  • 04 Sep, 2021
  • 71 locations
A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

The primary purpose of this study is to evaluate the efficacy and safety of a single intravenous (IV) re-induction dose of approximately 6 milligram per kilogram (mg/kg) ustekinumab in

antibiotics
ileocolitis
corticosteroids
ileitis
faecal calprotectin
  • 52 views
  • 08 Sep, 2021
  • 196 locations
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab. This

tumour necrosis
ustekinumab
tumor necrosis factor
crohn's disease
risankizumab
  • 97 views
  • 12 Sep, 2021
  • 484 locations
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

The purpose of this study is to evaluate the potential effects of an intravenous (IV) induction and subcutaneous (SC) maintenance administration of ustekinumab on the pharmacokinetic (PK) of a

ulcerative colitis
ileocolitis
crohn's disease
colitis
ileitis
  • 110 views
  • 06 Sep, 2021
  • 26 locations
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

fixed dose of risankizumab. Part 2: Participants aged 12 < 18 will receive; Period A: Risankizumab or ustekinumab based on body weight followed by; Period B: Risankizumab or

inflammatory disease
systemic therapy
ustekinumab
risankizumab
plaque psoriasis
  • 17 views
  • 15 Sep, 2021
  • 72 locations
Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group

Crohn's disease (CD), a chronic inflammatory process in intestinal segments leads to tissue damage. More than two thirds of CD patients need intestinal resection. Symptomatic clinical recurrence occurs in 60% by 10 years. The principal factors affecting postoperative recurrence are active smoking, penetrating disease, perianal lesions history, prior intestinal resection, …

thiopurines
tumor necrosis factor
crohn's disease
luminal
tumour necrosis
  • 9 views
  • 27 Mar, 2021
  • 17 locations
USTekinumab in Fistulising Perianal Crohn's Disease (USTAP)

track Investigational treatment : Group 1: Ustekinumab (UST) IntraVenous (IV) induction (6mg/kg) followed by UST SubCutaneous (SC) 90mg every 8 weeks. Group 2: Placebo IV followed by Placebo SC

  • 0 views
  • 01 Feb, 2021
  • 20 locations
Loss of RESponse to Ustekinumab Treated by Dose Escalation

The aim of the study is to investigate the effect of re-induction with ustekinumab 6mg/kg IV followed by two different maintenance dosing regimens 90 mg subcutaneous every 8 weeks (Q8W) vs 90 mg

faecal calprotectin
ustekinumab
ulceration
crohn's disease
ileitis
  • 3 views
  • 01 Aug, 2021
  • 1 location
Efficacy and Safety of Ustekinumab in Bullous Pemphigoid

corticosteroids, there is a high need for a safe maintenance therapy to avoid treatment side effects due to cumulative doses of corticosteroids over months. Newer therapeutic agents such as ustekinumab

  • 0 views
  • 24 Jan, 2021
  • 1 location